Anti-tumor effects of interferon-beta cell therapy in murine model of melanoma

Masaki Nakamura, Lisa Kagawa, Norihiro Nakada, Masashi Satoh, Shotaro Maehana, Fumiaki Kojima, Hideki Amano, Yoshiki Murakumo, Kazuya Iwabuchi, Masataka Majima, Hidero Kitasato


Purpose: Recombinant interferon beta (IFN-β) has been used for a treatment of cancers. However, the efficacy of recombinant IFN-β is limited because of its short half-life and side effects. To overcome these problems, we focused on the efficacy of cell-based therapy (cell therapy) using IFN-β-producing cells in the treatment of melanoma.

Methods: IFN-β-producing therapeutic cells were constructed by gene transduction using retrovirus vector. Anti-tumor effects of the cell therapy were investigated by a murine melanoma model.

Results: IFN-β cell therapy significantly suppressed the proliferation of B16 melanoma in vitro and the growth of B16-derived tumor in vivo, accompanied with the activation of natural killer (NK) cells. IFN-β cell therapy did not show any systemic side-effects concerning hepatic dysfunction and bone marrow suppression.

Conclusion: IFN-β cell therapy could be a candidate as a novel cancer treatment. 


Cell therapy, Interferon-beta, Melanoma

Full Text:



Uddin S, Platanias L. Mechanisms of Type-I interferon signal transduction. Journal of Biochemistry and molecular biology. 2004;37(6):635641.

Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2(4):336–52.

Sayers TJ, Wiltrout TA, McCormick K, et al. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res. 1990;50(17):5414–20.

Sakurai M, Iigo M, Sasaki Y, et al. [Direct and indirect antitumor effect of murine recombinant interferons].Gan To Kagaku Ryoho. 1987;14(3 Pt 2):889–95.

Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–86.

Ralph P, Nakoinz I, Rennick D. Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med. 1988;167(2):712–7.

Gidlund M, Orn A, Wigzell H, et al. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature. 1978;273(5665):759–61.

Fine HA, Wen PY, Robertson M, et al. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res. 1997;3(3):381–7.

Hsu C-SS, Chao Y-CC, Lin HH, et al. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep. 2015;5:9954.

Borden EC, Jacobs B, Hollovary E, et al. Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011;31(5):433–40.

Compagna R, Amato B, Massa S, et al. Cell Therapy in Patients with Critical Limb Ischemia. Stem Cells Int. 2015;2015:931420.

Fisher SA, Doree C, Mathur A, et al. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361–77.

Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015;116(9):1561–78.

Murakami Y, Akahoshi T, Kawai S, et al. Antiinflammatory effect of retrovirally transfected interleukin-10 on monosodium urate monohydrate crystal-induced acute inflammation in murine air pouches. Arthritis Rheum. 2002;46(9):2504–13.

Kosaka S, Tamauchi H, Terashima M, et al. IL-10 controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation. Immunobiology. 2011;216(7):811–20.

Watkins SK, Zhu Z, Watkins KE, et al. Isolation of immune cells from primary tumors. J Vis Exp. 2012;(64):e3952.

Yoshida J, Mizuno M, Wakabayashi T. Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004;95(11):858–65.

Ryuke Y, Mizuno M, Natsume A, et al. Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy. Melanoma Res. 2003;13(4):349–56.

McCarty MF, Bielenberg D, Donawho C, et al. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis. 2002;19(7):609–15.

Takano S, Ishikawa E, Matsuda M, et al. Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol. 2014;45(5):1837–46.

Kobayashi H, Nobeyama Y, Nakagawa H. Tumor-suppressive effects of natural-type interferon-β through CXCL10 in melanoma. Biochem Biophys Res Commun. 2015;464(2):416–21.

Antonicelli F, Lorin J, Kurdykowski S, et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol. 2011;164(4):720–8.

Schneble EJ, Yu X, Wagner TE, et al. Novel dendritic cell-based vaccination in late stage melanoma. Hum Vaccin Immunother. 2014;10(11):3132–8.

Karimi K, Karimi Y, Chan J, et al. Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity. Innate Immun. 2015;21(6):626–34.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the '' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013